SPERO THERAPEUTICS INC (SPRO)
US84833T1034 - Common Stock
Overall SPRO gets a fundamental rating of 5 out of 10. We evaluated SPRO against 588 industry peers in the Biotechnology industry. SPRO has only an average score on both its financial health and profitability. SPRO is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year SPRO was profitable.
SPRO had a negative operating cash flow in the past year.
In the past 5 years SPRO reported 4 times negative net income.
SPRO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 12.50%, SPRO belongs to the top of the industry, outperforming 98.12% of the companies in the same industry.
The Return On Equity of SPRO (21.33%) is better than 97.77% of its industry peers.
SPRO's Return On Invested Capital of 16.56% is amongst the best of the industry. SPRO outperforms 98.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.5% | ||
| ROE | 21.33% | ||
| ROIC | 16.56% |
ROA(3y)-25.72%
ROA(5y)-37.19%
ROE(3y)-47.16%
ROE(5y)-56.57%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SPRO's Profit Margin of 21.97% is amongst the best of the industry. SPRO outperforms 98.12% of its industry peers.
SPRO's Operating Margin of 25.82% is amongst the best of the industry. SPRO outperforms 97.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.82% | ||
| PM (TTM) | 21.97% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), SPRO is creating some value.
Compared to 1 year ago, SPRO has more shares outstanding
The number of shares outstanding for SPRO has been increased compared to 5 years ago.
SPRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
SPRO has an Altman-Z score of -0.72. This is a bad value and indicates that SPRO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.72, SPRO is in line with its industry, outperforming 57.36% of the companies in the same industry.
There is no outstanding debt for SPRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.72 |
ROIC/WACC1.77
WACC9.34%
2.3 Liquidity
SPRO has a Current Ratio of 3.53. This indicates that SPRO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SPRO (3.53) is worse than 60.79% of its industry peers.
SPRO has a Quick Ratio of 3.53. This indicates that SPRO is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.53, SPRO perfoms like the industry average, outperforming 41.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.53 | ||
| Quick Ratio | 3.53 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 131.33% over the past year.
Looking at the last year, SPRO shows a very strong growth in Revenue. The Revenue has grown by 93.95%.
Measured over the past years, SPRO shows a very strong growth in Revenue. The Revenue has been growing by 92.07% on average per year.
EPS 1Y (TTM)131.33%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q74.55%
Revenue 1Y (TTM)93.95%
Revenue growth 3Y123.23%
Revenue growth 5Y92.07%
Revenue growth Q2Q54.98%
3.2 Future
SPRO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.77% yearly.
SPRO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.62% yearly.
EPS Next Y-283.73%
EPS Next 2Y-96.72%
EPS Next 3Y-47.91%
EPS Next 5Y15.77%
Revenue Next Year-1.34%
Revenue Next 2Y-1.08%
Revenue Next 3Y4.79%
Revenue Next 5Y29.62%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 2.81, the valuation of SPRO can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of SPRO indicates a rather cheap valuation: SPRO is cheaper than 98.97% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of SPRO to the average of the S&P500 Index (24.92), we can say SPRO is valued rather cheaply.
SPRO is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.81 | ||
| Fwd PE | N/A |
4.2 Price Multiples
99.66% of the companies in the same industry are more expensive than SPRO, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.03 |
4.3 Compensation for Growth
A cheap valuation may be justified as SPRO's earnings are expected to decrease with -47.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-96.72%
EPS Next 3Y-47.91%
5. Dividend
5.1 Amount
No dividends for SPRO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SPERO THERAPEUTICS INC
NASDAQ:SPRO (4/26/2024, 7:17:16 PM)
After market: 1.49 +0.03 (+2.05%)1.46
+0.03 (+2.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap78.65M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.81 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.5% | ||
| ROE | 21.33% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 25.82% | ||
| PM (TTM) | 21.97% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.53 | ||
| Quick Ratio | 3.53 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)131.33%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-283.73%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)93.95%
Revenue growth 3Y123.23%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y